IDEAYA and Servier start Phase III adjuvant uveal melanoma study

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and Servier have dosed the first patient in OptimUM-11, a global Phase III registrational trial testing darovasertib plus crizotinib as adjuvant therapy after local treatment of primary uveal melanoma in patients at increased risk of metastasis. Approximately 450 participants will be randomized 1:1 to receive the combination for 12 months or undergo observation, regardless of HLA status, with relapse-free survival as the primary endpoint. No systemic drug is currently approved specifically for the adjuvant treatment of primary uveal melanoma, creating an opportunity for IDEAYA to move darovasertib earlier in the disease course. The strategic significance is amplified because the same combination is already moving through an FDA New Drug Application process for first-line metastatic uveal melanoma, meaning IDEAYA is building a lifecycle strategy before its first darovasertib approval has been secured.

IDEAYA retains United States regulatory and commercial rights to darovasertib, while Servier holds rights outside the United States and shares development costs. Darovasertib is an oral PKC inhibitor designed to block signalling downstream of GNAQ and GNA11 mutations, which occur in nearly all uveal melanoma patients. The drug remains investigational despite Fast Track, Orphan Drug and Breakthrough Therapy designations across different uveal melanoma settings.

Why is the adjuvant setting strategically larger than waiting for metastatic disease?

Primary uveal melanoma is usually treated locally through radiation or surgery, but successful treatment of the eye tumour does not eliminate the risk that microscopic cancer cells have already spread elsewhere. Patients with high-risk molecular or clinical features can later develop metastatic disease despite apparently successful local control.

Adjuvant therapy attempts to intervene during that window, before visible metastases develop. OptimUM-11 is therefore testing whether one year of darovasertib plus crizotinib can delay or prevent recurrence compared with observation alone.

If successful, treatment could begin earlier and potentially apply to a broader pool of patients than metastatic therapy alone. It could also extend the duration of drug exposure because patients would receive a defined 12-month course while clinically free of detectable metastatic disease.

The development bar is correspondingly demanding. Treating patients who may never recur requires a strong safety profile because some participants will be exposed to therapy even though observation alone might have left them disease-free for years.

Why does IDEAYA use relapse-free survival rather than tumour response in OptimUM-11?

Patients entering the study have already completed local therapy, so there may be no measurable tumour remaining to shrink. Traditional objective response rate is therefore not an appropriate primary measure of success.

Relapse-free survival measures how long patients remain alive without recurrent disease. The trial tests whether darovasertib plus crizotinib can extend that period compared with observation, directly addressing the clinical objective of adjuvant treatment.

A statistically significant improvement could support a registrational pathway if safety and overall benefit are persuasive. Regulators may also examine patterns of metastatic recurrence and longer-term survival as data mature.

The observation control creates a particularly clean comparison. Researchers can measure whether active systemic treatment changes the natural history of high-risk primary uveal melanoma instead of comparing one experimental regimen with another therapy whose adjuvant benefit is uncertain.

How does OptimUM-11 fit IDEAYA’s metastatic darovasertib programme?

IDEAYA has already initiated an NDA submission under the FDA Oncology Center of Excellence Real-Time Oncology Review programme for darovasertib plus crizotinib in first-line metastatic uveal melanoma and expects to complete the filing during the second half of 2026.

That filing follows positive Phase II/III OptimUM-02 data in HLA*A2-negative metastatic disease. IDEAYA reported median progression-free survival of 6.9 months with the combination compared with 3.1 months for investigator’s-choice therapy, corresponding to a 58% reduction in the risk of progression under the trial analysis. Objective response rate was 37.1% versus 5.8%.

Those results provide the clinical rationale for moving the combination earlier. A therapy capable of controlling established metastatic disease may potentially suppress microscopic residual disease before recurrence, although adjuvant success cannot be assumed from metastatic results.

The lifecycle strategy is ambitious because IDEAYA is simultaneously pursuing metastatic, neoadjuvant and adjuvant opportunities. If several settings succeed, darovasertib could become a treatment used at multiple stages of uveal melanoma rather than a single late-stage cancer drug.

Does IDEAYA have enough capital to run another global Phase III trial?

IDEAYA ended June with approximately $1.24 billion of cash, cash equivalents and marketable securities, up from $972.9 million at the end of March following equity financing. Management says the current operating plan provides cash runway into 2030.

The Servier partnership further alters the economics because the companies share development costs while IDEAYA recognizes collaboration revenue as research and development services are performed. IDEAYA reported $8.9 million of second-quarter collaboration revenue and approximately $147 million of remaining research-service performance obligations tied to anticipated Servier development reimbursements.

That balance-sheet position gives IDEAYA unusual flexibility for a biotechnology company running several registrational programmes. The primary investment risk is therefore less about immediate financing and more about whether clinical development produces enough regulatory and commercial value to justify the substantial R&D spending.

Second-quarter R&D expense exceeded $100 million and IDEAYA remains loss-making, so the $1.24 billion balance is not excess cash in an ordinary sense. It is financing for a broad oncology pipeline whose most advanced assets need to reach approval and commercialization before cash burn becomes structurally sustainable.

What does IDEAYA’s recent share price say ahead of the adjuvant trial?

IDEAYA shares closed at $38.35 on September 9, the day OptimUM-11 first-patient dosing was announced, down 1.26% for the session. The stock had closed at $39.97 on September 3, meaning it had declined roughly 4% over that interval despite the Phase III milestone.

A modest negative move does not establish that investors objected to OptimUM-11. The company already disclosed the planned study design months earlier, so first-patient dosing largely confirmed execution of a known programme rather than introducing a new clinical thesis.

Valuation is more likely to react to regulatory progress in metastatic disease, additional efficacy data and eventual evidence from the adjuvant trial. OptimUM-11 is expected to take substantially longer to mature because relapse-free survival requires enough recurrence events to distinguish treatment from observation.

IDEAYA is effectively investing today to widen darovasertib’s eventual commercial opportunity. The metastatic NDA could establish the initial franchise, while OptimUM-11 asks whether the same drug combination can become relevant before patients develop detectable metastatic disease.

What would make OptimUM-11 transformative for the darovasertib franchise?

The clearest outcome would be a statistically and clinically meaningful improvement in relapse-free survival without safety problems that outweigh the benefit of treating patients earlier.

Broad efficacy regardless of HLA status would increase the potential population compared with the initial metastatic regulatory programme, which focuses on an HLA-defined group. OptimUM-11 is specifically designed to enroll high-risk patients irrespective of HLA status.

Regulatory success in metastatic disease before OptimUM-11 reads out would also improve the commercial infrastructure supporting any eventual adjuvant launch. IDEAYA could establish physician familiarity, reimbursement and treatment pathways before attempting expansion into earlier disease.

The first patient has now been dosed, but this is the beginning rather than the conclusion of that strategy. The 450-person trial needs to prove that treating invisible residual disease can meaningfully alter recurrence risk.

Key takeaways on IDEAYA and Servier’s OptimUM-11 trial

• The first patient has been dosed in the global Phase III OptimUM-11 study.
• The trial plans to enroll approximately 450 patients.
• Participants are randomized 1:1 to darovasertib plus crizotinib for 12 months or observation.
• Enrollment is independent of HLA status.
• Relapse-free survival is the primary endpoint.
• There is currently no approved adjuvant drug specifically for primary uveal melanoma.
• IDEAYA retains U.S. rights while Servier holds rights outside the United States.
• A metastatic uveal melanoma NDA is already being submitted through FDA’s RTOR programme.
• IDEAYA had approximately $1.24 billion of cash, equivalents and marketable securities at June 30.
• Successful adjuvant development could move darovasertib substantially earlier in the uveal melanoma treatment pathway.